Compassionate use — formally known as expanded access — is a regulatory pathway that allows patients with serious or life-threatening conditions to access investigational therapies before those therapies receive full FDA approval. The FDA oversees this process and requires a treating physician to submit an Individual Patient Expanded Access request on behalf of a qualifying patient. The drug's manufacturer must also agree to provide the medication outside of a clinical trial setting.
As of August 2026, retatrutide has opened to compassionate use in the United States. This is a meaningful development for patients who have been following the drug's clinical trajectory closely. Retatrutide — commonly referred to as reta in patient communities — is a once-weekly subcutaneous injection that works as a triple agonist, simultaneously targeting GLP-1, GIP, and glucagon receptors. This triple-receptor mechanism, sometimes called "triple G" in patient forums, distinguishes reta from earlier generation GLP-1 receptor agonists and from dual agonists like tirzepatide.
The compassionate use opening does not represent FDA approval, and it does not guarantee that any individual patient will receive the medication. It does, however, signal that Eli Lilly and the broader regulatory ecosystem have reached a point where access outside of a formal trial structure is considered appropriate for carefully selected patients under physician oversight.
The eligibility framework for compassionate use is shaped in part by the inclusion and exclusion criteria used in retatrutide's Phase 2 and Phase 3 clinical trials. In the Phase 2 obesity trial published in the New England Journal of Medicine in 2023, participants were required to have a BMI of 30 kg/m² or higher, or a BMI of 27 kg/m² or higher with at least one weight-related comorbidity such as hypertension or dyslipidemia. Patients with type 2 diabetes were excluded from that trial.
For expanded access, the treating physician and the FDA evaluate each request individually. Generally speaking, compassionate use is most likely to be considered for patients who:
This is not a pathway for general consumer access. Patients should work closely with a qualified physician who can evaluate their individual clinical profile and determine whether submitting an expanded access request is appropriate and supportable.
In the months leading up to the August 2026 compassionate use announcement, public speculation circulated widely suggesting that former President Donald Trump had been taking retatrutide. These reports were never officially confirmed, but the timing drew significant attention to reta at a moment when TRIUMPH-4 Phase 3 data had already positioned it as the most effective pharmacological weight loss agent ever studied in a large randomized trial.
Whether or not that speculation was accurate, it accelerated public awareness of retatrutide's clinical profile and likely contributed to the surge in waitlist interest that preceded the compassionate use announcement. High-profile attention to a drug in late-stage clinical development can create meaningful pressure on manufacturers and regulators to expand access, particularly when the underlying clinical evidence is strong. The TRIUMPH-4 data — showing 28.7% mean weight loss at the 12mg dose over 68 weeks — gave that public interest a credible scientific foundation.
It would be overly simplistic to attribute the compassionate use opening solely to political speculation. The regulatory groundwork for expanded access is built on clinical data, safety monitoring, and manufacturer readiness. But the cultural moment surrounding the Trump speculation did bring retatrutide into mainstream conversation in a way that few investigational obesity drugs have experienced before FDA approval.
No. These are meaningfully different regulatory statuses, and the distinction matters for patients evaluating their options. The following table outlines the key differences:
| Feature | Compassionate Use (Expanded Access) | Full FDA Approval |
|---|---|---|
| Regulatory basis | Individual patient or intermediate-size request | New Drug Application (NDA) approval |
| Availability | Case-by-case; physician must apply | Broadly available by prescription |
| Insurance coverage | Typically not covered | Subject to formulary and plan coverage |
| Manufacturer requirement | Manufacturer must agree to provide drug | Drug available through standard supply chain |
| Retatrutide status (April 2026) | Open as of August 2026 | NDA not yet filed as of April 2026 |
As of April 2026, Eli Lilly had not yet filed a New Drug Application for retatrutide with the FDA, and no approval timeline had been publicly confirmed. The TRIUMPH-4 trial data — representing the highest mean weight loss ever recorded in a Phase 3 obesity trial — will form a central part of the eventual NDA submission, but the regulatory review process takes time regardless of how compelling the efficacy data may be.
Patients who have been tracking retatrutide's development through platforms like glp3md.com are already positioned to act quickly as the landscape evolves. Pursuing compassionate use access requires an engaged, informed physician who is willing to navigate the expanded access application process — and a patient who can clearly document their clinical history, prior treatment attempts, and current cardiometabolic status.
The clinical case for retatrutide is difficult to overstate. In the Phase 2 trial, 100% of participants in the 8mg arm achieved at least 5% weight loss by week 48, and up to 70% achieved 20% or greater weight loss. TRIUMPH-4 extended those results further, with 28.7% mean weight loss at 12mg over 68 weeks of treatment. Cardiometabolic improvements were also substantial: fasting triglycerides dropped by up to 39.3% and LDL cholesterol by up to 16.9% at 24 weeks in the Phase 2 data. For patients who have not achieved adequate results with approved agents — or who experience persistent food noise despite existing therapies — the clinical rationale for pursuing expanded access may be compelling.
Patients should also understand that reta carries dose-dependent gastrointestinal side effects including nausea, diarrhea, and vomiting, and that dysesthesia — an unusual skin sensation — occurred in 20.9% of participants at the 12mg dose in TRIUMPH-4. These are real clinical considerations that a physician must weigh alongside the efficacy data when evaluating individual patient suitability.
Joining the waitlist at glp3md.com is the first step toward staying informed as compassionate use access develops and as the path toward FDA approval continues to unfold. The waitlist is a way to signal interest and receive timely updates — it does not constitute enrollment in a clinical program, and no promises are made regarding treatment access, medication availability, or prescriptions of any kind. Retatrutide remains an investigational therapy, and access decisions will always rest with qualified physicians and regulatory bodies. That said, the patients who are informed and prepared when access expands are the ones best positioned to have meaningful conversations with their physicians about whether reta may be appropriate for them.
Join the waitlist for priority access to a prescribing physician when retatrutide receives FDA approval.
Join the WaitlistThis article is for educational purposes only and does not constitute medical advice. Retatrutide is an investigational drug and is not FDA approved as of publication. Clinical data referenced is from publicly available trial publications. Consult a qualified healthcare provider before making any treatment decisions.